Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer’s disease

Jay Rasmussen\(^{a,b,c,1}\), Jasmin Mahler\(^{a,c,1}\), Natalie Beschorner\(^{c,1}\), Stephan A. Kaeser\(^{a,b}\), Lisa M. Häsler\(^{a,b}\), Frank Baumann\(^{a,b}\), Sofie Nyström\(^{e}\), Erik Portelius\(^{e,f}\), Kaj Blennow\(^{e,f}\), Tammyrin Lashley\(^{g}\), Nick C. Fox\(^{h}\), Diego Sepulveda-Falla\(^{i,k}\), Markus Glatzel\(^{k}\), Adrian L. Oblak\(^{l}\), Bernardino Ghetti\(^{i}\), K. Peter R. Nilsson\(^{d}\), Per Hammarström\(^{d}\), Matthias Staufenbiel\(^{l}\), Lary C. Walker\(^{m,n}\), and Mathias Jucker\(^{a,b,2}\)

\(^{a}\)Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany; \(^{b}\)German Center for Neurodegenerative Diseases, 72076 Tübingen, Germany; \(^{c}\)Graduate School of Cellular and Molecular Neuroscience, University of Tübingen, 72074 Tübingen, Germany; \(^{d}\)Department of Physics, Chemistry and Biology, Division of Chemistry, Linköping University, SE-581 83 Linköping, Sweden; \(^{e}\)Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, SE-431 80 Mölndal, Sweden; \(^{f}\)Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, SE-431 80 Mölndal, Sweden; \(^{g}\)Queen Square Brain Bank for Neurological Diseases, Department of Molecular Neuroscience, Institute of Neuroscience, University College London, London WC1N 1PJ, United Kingdom; \(^{h}\)Dementia Research Centre, University College London, London WC1N 3BG, United Kingdom; \(^{i}\)Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; \(^{j}\)Neuroscience Group of Antioquia, University of Antioquia, 1226 Medellín, Colombia; \(^{k}\)Faculty of Medicine, University of Antioquia, 1226 Medellín, Colombia; \(^{l}\)Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202; \(^{m}\)Department of Neurology, Emory University, Atlanta, GA 30322; and \(^{n}\)Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329

Edited by Stephen M. Strittmatter, Yale University School of Medicine, New Haven, CT, and accepted by Editorial Board Member Solomon H. Snyder October 24, 2017 (received for review July 26, 2017)

The molecular architecture of amyloids formed in vivo can be interrogated using luminescent conjugated oligothiophenes (LCOs), a unique class of amyloid dyes. When bound to amyloid, LCOs yield fluorescence emission spectra that reflect the 3D structure of the protein aggregates. Given that synthetic amyloid-β peptide (Aβ) has been shown to adopt distinct structural conformations with different biological activities, we asked whether Aβ can assume structurally and functionally distinct conformations within the brain. To this end, we analyzed the LCO-stained cores of β-amyloid plaques in post-mortem tissue sections from frontal, temporal, and occipital neocortices in 40 cases of familial Alzheimer’s disease (AD) or sporadic (idiopathic) AD (sAD). The spectral attributes of LCO-bound plaques varied markedly in the brain, but the mean spectral properties of the amyloid cores were generally similar in all three cortical regions of individual patients. Remarkably, the LCO amyloid spectra differed significantly among some of the familial and sAD subtypes, and between typical patients with sAD and those with posterior cortical atrophy AD. Neither the amount of Aβ nor its protease resistance correlated with LCO spectral properties. LCO spectral amyloid phenotypes could be partially conveyed to Aβ plaques induced by experimental transmission in a mouse model. These findings indicate that polymorphic Aβ-amyloid deposits within the brain cluster as clouds of conformational variants in different AD cases. Heterogeneity in the molecular architecture of pathogenic Aβ among individuals and in etiologically distinct subtypes of AD justifies further studies to assess putative links between Aβ conformation and clinical phenotype.

Alzheimer | amyloid | neurodegeneration | prion | strains

Despite a common origin in the structural corruption and accumulation of specific proteins, the clinical and pathological phenotype of Alzheimer’s disease (AD) exhibits conspicuous variability within and among patients (1–4). The amyloid cascade hypothesis postulates that the seminal event in the pathogenesis of AD is the misfolding and aggregation of the amyloid-β peptide (Aβ) (5, 6). In vitro investigations have found that Aβ can aggregate into diverse amyloid structures that can impose their conformational characteristics onto naïve synthetic forms of the protein (7, 8). In Aβ precursor protein (APP)-transgenic mouse models, polymorphisms of aggregated Aβ have been demonstrated that subsequently could be propagated to naïve and susceptible host mice (9–11).

Recent work in humans suggests that Aβ can aggregate into structural variants with distinct pathobiological traits. One such study used extracted fibrils from AD brains to seed the aggregation of synthetic Aβ in vitro. The resulting synthetic descendants of aggregated Aβ from brain samples provided indirect evidence for structural heterogeneity of Aβ among AD brains; in addition, the findings suggested that Aβ assumes a single, dominant conformation within a given brain (12, 13). Another investigation has shown that the biophysical features of aggregated Aβ differ significantly in patients with rapidly progressive AD compared with those with normally progressive disease, indicative of distinct molecular structures of Aβ (14). In an exceptional example of Aβ aggregate structural variation in AD, a patient was described as having an extraordinarily high Aβ burden but a paucity of high-affinity Pittsburgh compound B (PIB) binding sites (15). More recently, X-ray microdiffraction analysis of

**Significance**

The clinical and pathological variability among patients with Alzheimer’s disease (AD) remains largely unexplained. Evidence is growing that this heterogeneity may be influenced by the heterogeneous molecular architecture of misfolded amyloid-β peptide (Aβ) in the brain. To test this hypothesis, we used unique fluorescent ligands to interrogate the molecular structure of Aβ in amyloid plaques from patients who had died with etiologically distinct subtypes of AD. We found that Aβ-amyloid plaques in the brain cluster as clouds of conformational variants that differ among certain subtypes of AD. The conformational features of AD plaques were partially transmissible to transgenic mice in a seeding paradigm, suggesting a mechanism whereby different molecular strains of Aβ propagate their features within the brain.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission. S.M.S. is a guest editor invited by the Editorial Board.

Published under the PNAS license.

1J.R., J.M., and N.B. contributed equally to this work.

2To whom correspondence should be addressed. Email: mathias.jucker@uni-tuebingen.de.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1713215114/-/DCSupplemental.
individual AD brain tissue samples indicated that the amyloid arrangement of Aβ is polymorphic within and among plaques (16).

Morphologically at the light-microscopic level, it is well documented that amyloid plaques in AD brains present with phenotypic variation that typically ranges from diffuse to dense-cored plaques (17–24). How such morphotypes are linked to the molecular conformation of the amyloid has not been established. The characterization of amyloid has been facilitated by a new class of dyes known as luminescent conjugated oligothiophenes (LCOs) or luminescent conjugated polythiophenes (25, 26). LCO dyes bind to the repetitive cross-β-sheet structures of amyloid fibrils and display spectral differences based on the twisting of the flexible LCO backbone (25, 27). Additionally, it was found that certain LCOs compete with a Congo red analog (X-34) for binding to recombinant Aβ-amyloid fibrils as well as AD brain-derived Aβ, but they do not compete for the PiB binding site (28). It has been demonstrated that LCOs can detect molecular differences in Aβ plaque structure in different APP-transgenic F105L and EAPP V717I PSEN1 A431E (PSEN1 A431E) was analyzed biochemically and PK resistance (Fig. 2 and E) with the Aβ amyloid structures that cluster as clouds across different patients with AD while encoding conformational characteristics that can be biologically propagated.

Results Spectral Characteristics of Plaque Amyloid in AD Brains. We evaluated plaque amyloid in tissue sections from a cohort of patients with AD of various etiologies, including familial mutation carriers for APP (V717I) and PSEN1 (A431E, F105L, and E280A), as well as cases of typical sporadic AD (sAD) and sporadic PCA-AD (Table S1). A double-stain combination with two LCOs, quadro-formyl thiophene acetic acid (qFTAA) and hepta-formyl thiophene acetic acid (hFTAA) (29, 30) (Methods), was used to label amyloid plaques in fresh-frozen brain sections. Subsequently, the dense (congophilic) cores of amyloid plaques were spectroscopically analyzed for fluorescence emission characteristics (Figs. S1 and S2). Three brain regions, the midtemporal gyrus (temporal), pericarotinal gyri (occipital), and midfrontal gyrus (frontal), were investigated for each patient (Fig. 1A). Preliminary visual inspection under the fluorescence microscope revealed obvious variation in plaque appearance even within a tissue section (Fig. 1B).

To determine how the molecular structure of plaque amyloid varies among brains and brain regions, the mean emission spectra were calculated for all plaques in each brain region of all subjects. Pairwise comparisons between individual patients were then performed using a Euclidean distance calculation (Fig. 1 C and D). This analysis revealed that the spectral signatures of plaque amyloid in familial APP V717I and PSEN1 A431E mutation carriers were most different from the other groups (Fig. 1C). Statistical analysis of the ratio of the emission peaks for qFTAA (502 nm) and hFTAA (588 nm) in individual plaque cores confirmed that the APP V717I and PSEN1 A431E groups were significantly different from most other groups (Fig. 1E). A difference was also found between sAD and PCA-AD cases (Fig. 1E). Of note, however, was the striking variability within the sAD group (Fig. 1 C and E), with one of the samples with a high LCO spectral ratio being a previously described case with reduced high-affinity binding of PiB (Fig. 1 C and E). To further interrogate the variability in LCO spectra among the groups, all data points from the analysis based on the correlation of fluorescence intensity at 502 nm and 588 nm were examined (Fig. 1F). Again, the spectral signatures of plaque amyloid in the different patient groups segregated into noticeable clouds that partially overlapped each other (Fig. 1F).

Amyloid Plaque Spectral Characteristics Compared with Other Metrics. To determine whether the results from the LCO spectral analysis of plaques could be explained by factors that affect amyloid deposition in the brain, LCO ratios were related to apolipoprotein E (ApoE) genotype, subject age at death, and postmortem interval (PMI) (Fig. 2). Only sAD and PCA-AD samples were used to remove obvious confounding effects that the familial mutations might have on the comparison (e.g., younger mean age at death). No correlation was found between spectral ratio and ApoE status or subject age at death (Fig. 2A–C). The correlation found between the spectral ratio and the PMI disappeared when sAD cases and PCA-AD cases were analyzed separately, reflecting the overall longer PMI for the PCA-AD samples (Fig. 2C). Thus, ApoE, age at death, and PMI are not crucial factors for the observed LCO spectral differences.

To assess whether the LCO results are related to the total Aβ load or the deposited Aβ species, Aβ was analyzed biochemically (Fig. S2). Overall, samples from the PSEN1 A431E group had higher Aβ levels than all other groups. The ratio of Aβ42/40 was higher in the APP V717I familial mutation carriers compared with the PSEN1 mutation carriers (Fig. S2). Neither the amount of Aβ nor the Aβ42/40 ratio differed significantly across the three neocortical regions; furthermore, the LCO spectra were not significantly associated with either total Aβ or the Aβ42/40 ratio when the analysis was confined to sAD and PCA-AD samples (Fig. 2 D and E).

Protease K (PK) resistance has been linked to pathogenic conformations of Aβ in mouse models and AD brains (11, 31, 32). To determine whether the LCO spectral signatures of the plaque cores are associated with protease sensitivity, the resistance of aggregated Aβ to proteolysis over time was evaluated (Fig. S2). No differences among patient groups were observed (Fig. S2). Furthermore, when only sAD and PCA-AD cases were considered, there was no significant correlation between the plaque spectral ratio and Aβ PK resistance (Fig. 2F).

Amyloid Plaque Spectral Characteristics Are Transmissible to Experimental Mouse Models. We next asked whether the LCO spectral properties of amyloid plaques can be propagated in vivo by the prion-like process of molecular conformational templating. To this end, cortical extracts from AD groups showing the most distinct LCO spectra, namely, APP V717I, PSEN1 A431E, and sAD, in addition to the unique PiB-negative sAD case, were injected into the hippocampus of young APP23-transgenic mice (Fig. 3). APP23 mice were used for this analysis because they have recently been characterized in a seeding activity bioassay in which the precise biological activity of brain extracts was assessed (33). Before injection, all extracts were pooled for each AD group and the Aβ concentration was adjusted to 7.5 pg/μL. Since we found that the LCO spectral characteristics of plaques did not differ significantly among the three brain regions, we arbitrarily chose temporal cortical samples as the source of Aβ seeds.

Inoculated APP23 mice were analyzed 6 mo after injection (Fig. 3/4). In all mice, Aβ deposition was induced in the hippocampus (primarily the dentate gyrus) as reported previously (9, 33). While this regional pattern of induction was not discernibly different among the groups, the amount of induction showed remarkable differences, with mice injected with APP V717I and typical sAD extracts manifesting at least twice as much induced Aβ deposition as mice injected with material from PSEN1 A431E donors or from the PiB-refractory sAD donor (Fig. 3 A and B).
Subtypes of AD display distinguishable clouds of amyloid conformational variants. (A) Combination of two LCOs, qFTAA and hFTAA, was used to stain Aβ plaques in three different neocortical regions (temporal: midtemporal gyrus, T; occipital: pericalcarine gyri, O; frontal: midfrontal gyrus, F) of postmortem brain tissue from familial AD (APP V717I, PSEN1 A431E, PSEN1 F105L, and PSEN1 E280A), typical sAD, and sporadic PCA-AD cases. (B) Shown is an LCO-stained section of the temporal cortex from a patient with sAD (AD16; also patient information in Table S1). Note that a variety of different fluorescence emission patterns are present in a single brain sample. (Scale bars: Left, 200 μm; Right, 20 μm.) (C and D) Plaques were randomly selected, and for each plaque core, the fluorescence intensity was measured at 22 wavelengths to produce a continuous fluorescence spectrum (40-60 plaques were analyzed per region for each brain sample; also Fig. S1). Each line in D represents the mean spectrum for a particular brain area in all patients in a given subgroup. A heat map depicting the difference of Euclidean distances between the mean spectra (of all 22 fluorescence measurements) for brain regions of individual patients is shown in C. Larger and more darkly colored circles represent more dissimilar spectra. The labels represent patient numbers with the temporal, occipital, and frontal regions repeating as sets of three (from top to bottom). Note the variability within the sAD group, with some regions yielding emission spectra more similar to those of the familial groups (for AD2, only temporal and occipital cortex tissue was available for analysis). (E) For statistical analysis, the fluorescence intensity at 502 nm and 588 nm (which represent the fluorescence emission peaks of qFTAA and hFTAA, respectively; Fig. S1C) was analyzed for each region of each patient. Two-way ANOVA (brain region × AD subtype) revealed a significant effect for subtype $F_{0.03,010} = 33.07, P < 0.0001$, but not for brain region $F_{0.03,010} = 0.0681, P = 0.9334$ or interaction between region and subtype $F_{0.03,010} = 0.7829, P = 0.6451$. Tukey’s multiple comparisons revealed significant differences between APP V717I vs. PSEN1 A431E, APP V717I vs. PSEN1 F105L, PSEN1 E280A, sAD and PCA-AD; PSEN1 A431E vs. PSEN1 F105L, PSEN1 E280A, sAD and PCA-AD; PSEN1 F105L vs. PSEN1 E280A, sAD and PCA-AD; and sAD vs. PCA-AD (all probabilities at least $P < 0.05$). An exceptional sAD case, AD34 (denoted by arrows in C and E), is a previously described case with reduced high-affinity binding of the PiB radioligand (15). Error bars represent the SEM. (F) Scatter plot of all plaques analyzed using fluorescence at 588 nm vs. 502 nm per AD subgroup reveals that plaque spectral properties within the AD subgroups occupy distinct clouds, which overlap between AD subgroups.

Strikingly, when brain sections from the recipient mice were stained using the same LCO protocol as that used for the human tissue (Fig. 1), quite remarkable differences in the emission spectra of individual plaque cores were observed (Fig. 3A). The mean emission spectra of all seeded hippocampal plaque cores were computed for each injected mouse, and a Euclidean distance calculation was applied to determine differences (Fig. 3C). Similar to the LCO spectral patterns in plaques from the human donors, seeded amyloid in the PSEN1 A431E-injected mouse was most different from that in the sAD groups, albeit with more variation (Fig. 3C and D). For statistical comparison of the experimental groups, the 502-nm/588-nm spectral ratio was calculated for each plaque core, and the mean ratios for each injected mouse were computed (Fig. 3D and E). The spectral ratios in the different groups of seeded host mice displayed relatively similar patterns to those in the donor humans (compare Figs. 1E and 3E); the group difference was statistically significant between PSEN1 A431E- and sAD-seeded mice, but the other group differences did not reach statistical significance. The amount of induced Aβ deposition did not correlate with the spectral ratio, suggesting these two factors are independent (Fig. 3F). As with the human tissue, all plaque cores analyzed in the mice were plotted based on the fluorescence intensity at 502 nm against 588 nm (Fig. 3G). The plaques in seeded mice occupied similar clouds within an injection group, although these clouds showed more overlap in the injected mice than in the original human tissue (Fig. 1), suggestive of differential host–agent interactions (9).

**Discussion**

The extraordinary phenotypic variability of AD (1–3) currently defies explanation. It is likely that many factors are involved, including the age at disease onset, location of the initial abnormalities in the brain and their pattern of spread, the inflammatory response to the lesions, and the presence of comorbid conditions. The present findings support growing evidence that the heterogeneity of AD may also be influenced by the heterogeneous molecular architecture of misfolded Aβ in the brain.

Using synthetic Aβ that was aggregated in vitro, multimeric Aβ assemblies have been shown to assume diverse tertiary and quaternary structures (13, 34–37). These findings have greatly augmented our understanding of Aβ fibril structure, but their relevance to the pathobiology of Aβ in vivo, in the native disease
in the living brain (39, 40). Tycko and coworkers (12, 13) have demonstrated that Aβ derived from different cases of AD is able to induce synthetic Aβ to assemble into corresponding structural "strains," and the authors suggest that a single Aβ structure predominates in a particular AD brain. Our observations generally support the concept of a predominant, case-specific Aβ strain in that the mean LCO spectral emission of plaque cores (where the Aβ adopts an amyloid conformation) was similar in different cortical regions of each patient, regardless of the AD subtype. However, direct microscopic analysis of individual plaque cores with LCOs allowed us to determine that minor populations of Aβ aggregates with different molecular architectures also are present within a given AD brain. We therefore speculate that the presence of these structural variants in other investigations (12, 13) may have been masked by the conformational selection and in vitro propagation of a dominant strain in preparation for the NMR analysis. In support of this possibility, and in agreement with our findings, X-ray microdiffraction analysis has revealed structural polymorphism among amyloid plaques within the same tissue section (16).

In light of the intra- and interindividual variability in the LCO spectral characteristics of plaque amyloid, it is remarkable that we still found differences among patient subgroups, particularly between some of the familial AD and sAD cases (note that the familial AD mutations in the present study do not change the Aβ sequence). Neuropathological analyses also have revealed differences in plaque morphotypes between some familial AD mutations and sAD (18, 20, 23). However, while these observations were made on Aβ-immunostained plaques, our LCO-based spectral analysis was confined to the core of the plaque, and thus to Aβ in the amyloid conformation.

We were somewhat surprised to observe differences in the amyloid spectral characteristics between typical patients with sAD and patients with the PCA variant of AD. Both the regional distribution of amyloid and the clinical phenotype are different in PCA-AD and sAD (41). A previous NMR analysis did not indicate molecular structural differences between PCA-AD and sAD (13), but, as noted above, the analysis could have been confounded by conformational selection of Aβ species best suited for the seeded in vitro growth of fibrils. The clinicopathological distinctiveness of PCA-AD appears to result, in part, from a disease-specific site of origin and/or pattern of Aβ dissemination (41), but our findings indicate that the molecular architecture of misfolded Aβ may also play a role. Similarly, in a rapidly progressive subtype of AD, there is biochemical evidence for increased conformational heterogeneity of Aβ (14), and a recent NMR study using seeded growth of synthetic Aβ fibrils from brain-derived material supports this finding (13).

In the present study, the LCO spectral characteristics of amyloid in plaques did not correspond in a consistent way to the PK resistance or the abundance of the two major Aβ species (Aβ40 and Aβ42) in tissue homogenates. One possible explanation for this is that the spectral analysis and biochemical tests do not probe identical populations of Aβ [i.e., the amyloid core (LCOs) vs. the total pool of aggregated Aβ (biochemistry)]. Another possibility is that variation in amyloid structure revealed by the LCO spectral analysis is more sensitive at identifying subtle differences that biochemical analyses currently are unable to detect. Elucidation of the mechanisms underlying the architectural variability of Aβ in plaques could reveal pathogenically important targets for the development of personalized treatments for AD.

LCO binding and spectra are dependent on the orientation, side-chain interactions, and packing of amyloid fibrils, and the ability of LCOs to recognize amyloid features in protein pathologies has been well characterized (25). These ligands thus are exquisitely sensitive indicators of molecular architectural differences in proteopathic fibrils, for example, the strain-like diversity of prion protein aggregates (42). In recent studies, it has been shown that the arrangement and packing of Aβ-amyloid fibrils influence the spectral output of the LCOs, especially when the ligands are used in combination (29, 30, 43). Since LCO spectra indicate the presence of different structural conformations of Aβ, we predicted from previous experiments that these properties should be transmissible to susceptible hosts (44). Our studies in APP-transgenic mice confirm that Aβ-rich brain extracts from different subtypes of AD seed Aβ deposits that are correspondingly differentiable using LCOs. The LCO spectral traits of amyloid in the seeded transgenic mice did not perfectly mirror those of the human donor tissue; however, this is expected because both

![Image](https://example.com/image.png)

**Fig. 2.** Spectral properties of LCO-labeled amyloid plaques are not explained by ApoE genotype, patient age, PMI, or Aβ biochemistry. (A) LCO spectral ratio of fluorescence at 502 nm and 588 nm separated into ApoE genotype subgroups (mean of the three regions; Fig. 1E; only subjects with sAD and PCA-AD were used to remove the confounding effects of the familial mutations on the data; orange triangles, sAD; cyan diamonds, PCA-AD). The Mann–Whitney test was used to determine significance between ApoE 3/3 vs. 3/4 cases (P = 0.4221). Error bars represent the SEM. (B) LCO spectral ratio vs. patient age. Nonparametric Spearman correlation: P = 0.38. (C) LCO spectral ratio vs. PMI. Nonparametric Spearman correlation: P = 0.29 for PCA-AD and P = 0.32 for sAD. (D and E) LCO spectral ratios vs. ELISA measurements (mean of all brain regions) of Aβ 40 + 42 and the Aβ42/40 ratio (Aβ measurements are shown in Fig. S2). Nonparametric Spearman correlation analysis yielded P = 0.26 and P = 0.81, respectively. (F) LCO spectral ratio vs. Aβ remaining after 1 h of digestion with PK (mean of all brain regions). Nonparametric Spearman correlation: P = 0.78. Detailed results for PK digestion are shown in Fig. S3.
the agent and host influence the propagation of Aβ and the characteristics of the resulting deposits (9). In addition, the mice were seeded with extracts of brain tissue, which may have a seed composition that differs from that in the plaque cores. The existence of LCO spectral clouds that only partially recapitulate those of the AD donors thus may reflect the composition of seeds in the donor extract as well as the Darwininan selection of different Aβ strains in the host mice (45).

The spectral properties of LCOs bound to plaques change as APP-transgenic mice grow older, suggestive of age-related conformational rearrangement of the Aβ (30). Thus, it is possible that the spectral variation of plaques in individual patients with AD at least partially reflects the presence of plaques of different ages. The AD brains analyzed in the present study were all from patients with end-stage disease, at which point amyloid, per se, may no longer be the primary driver of the disease (46). Nevertheless, the deposited amyloid shows remarkable LCO spectral variability among patients with sporadic end-stage AD. Furthermore, the LCO spectral signals detected within an individual brain but negligible high-affinity binding of PiB (15). We found that the plaque cores in this case displayed an LCO spectral pattern that differed from that of most other sAD cases. If antibody binding to Aβ is similarly influenced by the molecular architecture of the misfolded protein, it is conceivable that a particular monoclonal antibody might fail to recognize the full range of Aβ aggregates that can arise within a brain and among different patients. Thus, it may be advantageous to use multiple antibodies to create a “polyclonal” mixture for treatment of Aβ pathology. Finally, future work should investigate the therapeutic potential of LCOs for AD and other proteopathies, as has been shown for prion disease (27), and, additionally, determine the feasibility of using LCOs to examine Aβ aggregates in bodily fluids such as cerebrospinal fluid and blood to augment the personalized diagnosis of AD.

**Methods**

**Patient Samples.** Fresh tissue samples were obtained from the midtemporal gyrus (temporal), pericalcarine gyr (occipital), and midfrontal gyrus (frontal) of 40 clinically and pathologically diagnosed AD cases (Table S1). The tissues were acquired under the proper Institutional Review Board protocols from the Tübingen Review Board for the work in the Queen Square Brain Bank at University College London samples (202/2016BO2), the Emory University Alzheimer’s Disease Research Center to do the work on these samples (IRB 00045782), and the University of Antioquia, Medellin, Colombia (09-10-232). Informed consent was given by families (see SI Methods for details).
Brain amyloid fibrils and seeds are potent inducers of cerebral amyloid deposits.

In Vivo Inoculations of the Mice. Seeding extracts were generated from the middle temporal gyrus (33). Pooled extracts [APP V7171 (AD1–3), PSEN A431E (AD4–6), and typical sAD (AD15, AD16, and AD24)] and the distinct PIB-negative sAD case (AD34) (Table S1) were adjusted to the same AJ concentration. Intrahippocampal injections were done in 4-mo-old APP23 mice (49). After 6 mo of incubation, brain sections were AJ-immunostained and quantified (50, 51).